Clario releases 20 years of data working on decentralized trials
Clario provides endpoint solutions for decentralized, hybrid and site-based clinical trials, and chose to outline the work it has carried out over the last 20 years on remote data collection.
The company outlined the data points that it had contributed to through its work in the industry and assisting in the operation of decentralized trials (DCTs), which allowed it to state that it had supported more than 1,000 potential medicines through its remote data collection technologies.
More than 2.6 million patients have participated in Clario’s DCTs, across more than 4,000 clinical trials.
“Clario recognized 20 years ago that there was a need to develop tools and technology to enable data collection for clinical trials outside the clinical setting. We saw that patients and sponsors needed more flexibility and released our first technology for remote data collection,” said Terry Burke, EVP, eCOA at Clario.
Since that time, DCTs have seen increased uptake across the industry, as creating more flexible clinical trials became necessary due to the impact of the pandemic. As a result, more and more companies are releasing their own tools and capabilities in the space.
When Outsourcing-Pharma asked Bryan McDowell, VP, ECOA Science and Consulting at Clario, what made the company’s services stand out from rivals in the area, he replied: “Our years of experience. We released our first technology for remote data capture more than 20 years ago!”
He continued, “Clario's broad endpoint technology platform enables the largest number of outcome assessments that can be captured at home, near home or at the investigational site.”
The company offers eCOA, respiratory, cardiac safety, precision motion, and medical imaging solutions, which can be used globally.
According to McDowell, the range of endpoint technology and services for decentralized or hybrid trials allow companies to limit the number of technology vendors that they have to engage with to set up their trials.
Joe Eazor, who stepped down as CEO in July 2022, previously provided an example of how Clario’s range of solutions can deliver benefits.
“An oncology patient might be required to receive a battery of different tests as part of their enrollment in a particular trial. That patient might not feel well and is asked to log information in multiple places, which can cause undue stress, and ultimately result in a patient dropping out of a trial. If we can streamline and simplify that effort, we can truly move the needle, reduce the room for error, and improve outcomes,” Eazor said.
The company states that all remote data collection technologies are designed from the patient perspective because study participants, rather than trained healthcare professionals, will need to collect the endpoint data.
Clario was formed last year through the merger of ERT and Bioclinica. The deal combined ERT’s clinical endpoint data capabilities with Bioclinica’s imaging, eClinical and drug-safety solutions.
